Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Ocupress

&times

Overview

What is Ocupress?

Ocupress (carteolol hydrochloride ophthalmic solution), 1%, is a nonselective beta-adrenoceptor blocking agent for ophthalmic use.

The chemical name for carteolol hydrochloride is (±)–5–[3–[(1,1–dimethylethyl) amino]–2 hydroxypropoxy]–3, 4–dihydro–2(1)–quinolinone monohydrochloride. The structural formula is as follows:

Each mL contains 10 mg carteolol HCl and the inactive ingredients – Benzalkonium chloride 0.05 mg (0.005%) as a preservative; sodium chloride; sodium phosphate, dibasic; sodium phosphate, monobasic; and water for injection, USP. The product has a pH of 6.2 to 7.2



What does Ocupress look like?



What are the available doses of Ocupress?

Sorry No records found.

What should I talk to my health care provider before I take Ocupress?

Sorry No records found

How should I use Ocupress?

Sorry No records found


What interacts with Ocupress?

Sorry No Records found


What are the warnings of Ocupress?

Sorry No Records found


What are the precautions of Ocupress?

Sorry No Records found


What are the side effects of Ocupress?

Sorry No records found


What should I look out for while using Ocupress?

Ocupress Ophthalmic Solution is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see WARNINGS); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (see WARNINGS); cardiogenic shock; or hypersensitivity to any component of this product.

Ocupress Ophthalmic Solution has not been detected in plasma following ocular instillation. However, as with other topically applied ophthalmic preparations, Ocupress may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported with topical application of beta-adrenergic blocking agents (see CONTRAINDICATIONS).


What might happen if I take too much Ocupress?

No specific information on emergency treatment of overdosage in humans is available. Should accidental ocular overdosage occur, flush eye(s) with water or normal saline. The most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension.

In case of ingestion, treatment with Ocupress should be discontinued and gastric lavage considered. The patient should be closely observed and vital signs carefully monitored. The prolonged effects of carteolol must be considered when determining the duration of corrective therapy. On the basis of the pharmacologic profile, the following additional measures should be considered as appropriate:

Symptomatic Sinus Bradycardia or Heart Block:

Bronchospasm:

Congestive Heart Failure:

Hypotension:


How should I store and handle Ocupress?

Ocupress Ophthalmic Solution, 1%, is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 58768-001-01), 10 mL (NDC 58768-001-02) and 15 mL (NDC 58768-001-04).Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.Rx OnlyLicensed under U.S. Patent Nos. 3910924 and 4309432.Made in Canada by:CIBA Vision Sterile Mfg.,Mississauga, Ontario L5N 2X5For: Novartis Ophthalmics, Duluth, Georgia 30097I6138-BOcupress Ophthalmic Solution, 1%, is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 58768-001-01), 10 mL (NDC 58768-001-02) and 15 mL (NDC 58768-001-04).Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.Rx OnlyLicensed under U.S. Patent Nos. 3910924 and 4309432.Made in Canada by:CIBA Vision Sterile Mfg.,Mississauga, Ontario L5N 2X5For: Novartis Ophthalmics, Duluth, Georgia 30097I6138-BOcupress Ophthalmic Solution, 1%, is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 58768-001-01), 10 mL (NDC 58768-001-02) and 15 mL (NDC 58768-001-04).Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.Rx OnlyLicensed under U.S. Patent Nos. 3910924 and 4309432.Made in Canada by:CIBA Vision Sterile Mfg.,Mississauga, Ontario L5N 2X5For: Novartis Ophthalmics, Duluth, Georgia 30097I6138-BOcupress Ophthalmic Solution, 1%, is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 58768-001-01), 10 mL (NDC 58768-001-02) and 15 mL (NDC 58768-001-04).Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.Rx OnlyLicensed under U.S. Patent Nos. 3910924 and 4309432.Made in Canada by:CIBA Vision Sterile Mfg.,Mississauga, Ontario L5N 2X5For: Novartis Ophthalmics, Duluth, Georgia 30097I6138-BOcupress Ophthalmic Solution, 1%, is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 58768-001-01), 10 mL (NDC 58768-001-02) and 15 mL (NDC 58768-001-04).Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.Rx OnlyLicensed under U.S. Patent Nos. 3910924 and 4309432.Made in Canada by:CIBA Vision Sterile Mfg.,Mississauga, Ontario L5N 2X5For: Novartis Ophthalmics, Duluth, Georgia 30097I6138-BOcupress Ophthalmic Solution, 1%, is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 58768-001-01), 10 mL (NDC 58768-001-02) and 15 mL (NDC 58768-001-04).Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.Rx OnlyLicensed under U.S. Patent Nos. 3910924 and 4309432.Made in Canada by:CIBA Vision Sterile Mfg.,Mississauga, Ontario L5N 2X5For: Novartis Ophthalmics, Duluth, Georgia 30097I6138-BOcupress Ophthalmic Solution, 1%, is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 58768-001-01), 10 mL (NDC 58768-001-02) and 15 mL (NDC 58768-001-04).Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.Rx OnlyLicensed under U.S. Patent Nos. 3910924 and 4309432.Made in Canada by:CIBA Vision Sterile Mfg.,Mississauga, Ontario L5N 2X5For: Novartis Ophthalmics, Duluth, Georgia 30097I6138-BOcupress Ophthalmic Solution, 1%, is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 58768-001-01), 10 mL (NDC 58768-001-02) and 15 mL (NDC 58768-001-04).Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.Rx OnlyLicensed under U.S. Patent Nos. 3910924 and 4309432.Made in Canada by:CIBA Vision Sterile Mfg.,Mississauga, Ontario L5N 2X5For: Novartis Ophthalmics, Duluth, Georgia 30097I6138-BOcupress Ophthalmic Solution, 1%, is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 58768-001-01), 10 mL (NDC 58768-001-02) and 15 mL (NDC 58768-001-04).Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.Rx OnlyLicensed under U.S. Patent Nos. 3910924 and 4309432.Made in Canada by:CIBA Vision Sterile Mfg.,Mississauga, Ontario L5N 2X5For: Novartis Ophthalmics, Duluth, Georgia 30097I6138-B


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Carteolol HCl is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity.

Ocupress (carteolol HCl) reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by glaucoma. The exact mechanism of the ocular hypotensive effect of beta-blockers has not been definitely demonstrated.

In general, beta-adrenergic blockers reduce cardiac output in patients in good and poor cardiovascular health. In patients with severe impairment of myocardial function, beta-blockers may inhibit the sympathetic stimulation necessary to maintain adequate cardiac function. Beta-adrenergic blockers may also increase airway resistance in the bronchi and bronchioles due to unopposed parasympathetic activity.

Given topically twice daily in controlled domestic clinical trials ranging from 1.5 to 3 months, Ocupress produced a median percent reduction of IOP 22% to 25%. No significant effects were noted on corneal sensitivity, tear secretion, or pupil size.

Non-Clinical Toxicology
Ocupress Ophthalmic Solution is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see WARNINGS); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (see WARNINGS); cardiogenic shock; or hypersensitivity to any component of this product.

Ocupress Ophthalmic Solution has not been detected in plasma following ocular instillation. However, as with other topically applied ophthalmic preparations, Ocupress may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported with topical application of beta-adrenergic blocking agents (see CONTRAINDICATIONS).

Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade.

Array

Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.

Ocupress Ophthalmic Solution should be used with caution in patients with known hypersensitivity to other beta-adrenoceptor blocking agents.

Use with caution in patients with known diminished pulmonary function.

In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen the angle. This requires constricting the pupil with a miotic. Ocupress has little or no effect on the pupil. When Ocupress is used to reduce elevated intraocular pressure in angle-closure glaucoma, it should be used with a miotic and not alone.

The following adverse reactions have been reported in clinical trials with Ocupress Ophthalmic Solution:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).